[ad_1]

  • Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 395, 795–808 (2020).

    Article 
    PubMed 

    Google Scholar 

  • The Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273–1285 (2023).

    Article 

    Google Scholar 

  • Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937–952 (2004).

    Article 
    PubMed 

    Google Scholar 

  • Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).

    Article 
    PubMed 

    Google Scholar 

  • Cholesterol Treatment Trialists’ Consortium. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).

    Article 

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527–1535 (2003).

    Article 

    Google Scholar 

  • Marcus, M. E. et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob. Health 10, e369–e379 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nelson, A. J. et al. Use of lipid, blood pressure, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw. Open 5, e2148030 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yusuf, S. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378, 1231–1243 (2011).

    Article 
    PubMed 

    Google Scholar 

  • Secondary prevention of noncommunicable diseases in low- and middle-income countries through community-based and health service interventions: World Health Organization–Wellcome Trust meeting report, 1–3 August 2001. World Health Organization https://apps.who.int/iris/handle/10665/42567 (2002).

  • Joseph, P. et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 398, 1133–1146 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Castellano, J. M. Polypill strategy in secondary cardiovascular prevention. N. Engl. J. Med. https://doi.org/10.1056/nejmoa2208275 (2022).

  • Bahiru, E. et al. Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd009868.pub3 (2017).

  • Cates, et al. Fixed‐dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst. Rev. CD009868 https://doi.org/10.1002/14651858.cd009868.pub2 (2014).

  • Zamorano, J. et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr. Med. Res. Opin. 27, 821–833 (2011).

    Article 
    PubMed 

    Google Scholar 

  • Neutel, J. M. et al. The use of a single‐pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo‐controlled, multicenter study. J. Clin. Hypertens. 11, 22–30 (2009).

    Article 
    CAS 

    Google Scholar 

  • Castellano, J. M. et al. A polypill strategy to improve adherence results from the FOCUS project. J. Am. Coll. Cardiol. 64, 2071–2082 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Selak, V. et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Br. Med. J. 348, g3318 (2014).

    Article 

    Google Scholar 

  • Patel, A. et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur. J. Prev. Cardiol. 22, 920–930 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Malekzadeh, F. et al. A pilot double‐blind randomised placebo‐controlled trial of the effects of fixed‐dose combination therapy (‘polypill’) on cardiovascular risk factors. Int. J. Clin. Pr. 64, 1220–1227 (2010).

    Article 
    CAS 

    Google Scholar 

  • Park, J.-S. et al. Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong). Drug Des. Dev. Ther. 10, 2599–2609 (2016).

    Article 
    CAS 

    Google Scholar 

  • PILL Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill (‘polypill’) in people with raised cardiovascular risk. PLoS ONE 6, e19857 (2011).

    Article 
    PubMed Central 

    Google Scholar 

  • Soliman, E. Z. et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials https://doi.org/10.1186/1745-6215-12-3 (2011).

  • The Indian Polycap Study (TIPS). Effects of a polypill (polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373, 1341–1351 (2009).

  • Grimm, R. et al. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc. Health Risk Manag. 6, 261–271 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Thom, S. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310, 918–929 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wald, D. S., Morris, J. K. & Wald, N. J. Randomized polypill crossover trial in people aged 50 and over. PLoS ONE 7, e41297 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kim, S.-H. et al. Blood pressure and cholesterol-lowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and hypercholesterolemia: a randomized, double-blind, factorial, multicenter phase III study. Clin. Ther. 38, 2171–2184 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Oh, G. C. et al. Efficacy and safety of fixed-dose combination therapy with telmisartan and rosuvastatin in Korean patients with hypertension and dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a multicenter, randomized, 4-arm, double-blind, placebo-controlled, phase III study. Clin. Ther. 40, 676–691.e1 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Cho, K. I. et al. Efficacy and safety of a fixed-dose combination of candesartan and rosuvastatin on blood pressure and cholesterol in patients with hypertension and hypercholesterolemia: a multicenter, randomized, double-blind, parallel phase III clinical study. Clin. Ther. 41, 1508–1521 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Muñoz, D. et al. Polypill for cardiovascular disease prevention in an underserved population. N. Engl. J. Med. 381, 1114–1123 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Roshandel, G. et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 394, 672–683 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chung, S. et al. Effect of FIXed-dose combination of ARb and statin on adherence and risk factor control: the randomized FIXAR study. Cardiol. J. 29, 815–823 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mariani, J. et al. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Ther. Adv. Cardiovasc. Dis. 14, 1753944720912071 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Choi, J. et al. Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: a pilot study. J. Clin. Hypertens. 23, 1664–1674 (2021).

    Article 

    Google Scholar 

  • González-Juanatey, J. R. et al. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev. Esp. Cardiol. Engl. Ed. 74, 51–58 (2021).

    Article 
    PubMed 

    Google Scholar 

  • Yusuf, S. et al. Polypill with or without aspirin in persons without cardiovascular disease. N. Engl. J. Med. 3, 216–228 (2021).

    Article 

    Google Scholar 

  • Merat, S. et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur. Heart J. 21, 2023–2033 (2022).

    Article 

    Google Scholar 

  • Kim, W. et al. A randomized, double‐blind clinical trial to evaluate the efficacy and safety of a fixed‐dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. J. Clin. Hypertens. 22, 261–269 (2020).

    Article 
    CAS 

    Google Scholar 

  • Zhu, J. Z. et al. Medication use for cardiovascular disease prevention in 40 low- and middle-income countries. J. Am. Coll. Cardiol. 81, 620–622 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yusuf, S. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. 374, 2032–2043 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jahangiri, R. et al. Cost-effectiveness of fixed-dose combination pill (polypill) in primary and secondary prevention of cardiovascular disease: a systematic literature review. PLoS ONE 17, e0271908 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lamy, A. et al. The cost implications of a polypill for primary prevention in the TIPS-3 trial. Eur. Hear. J. Qual. Care Clin. Outcomes 8, 899–908 (2021).

    Article 

    Google Scholar 

  • Abimbola, S. & Liu, H. Adoption and scale-up of the cardiovascular polypill: a realist institutional analysis. Health Policy Plan. 1, 15–27 (2023).

    Article 

    Google Scholar 

  • Huffman, M. D., Xavier, D. & Perel, P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 389, 1055–1065 (2017).

    Article 
    PubMed 

    Google Scholar 

  • Huffman, M. D., Salam, A. & Patel, A. Implementation strategies for cardiovascular polypills. JAMA 322, 2279–2280 (2019).

    Article 
    PubMed 

    Google Scholar 

  • Huffman, M. D. & Yusuf, S. Polypills essential medicines for cardiovascular disease secondary prevention? J. Am. Coll. Cardiol. 63, 1368–1370 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Webster, R. et al. An electronic decision support‐based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Med J. Aust. 214, 420–427 (2021).

    Article 
    PubMed 

    Google Scholar 

  • Rao, S. et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials. Prog. Cardiovasc. Dis. 73, 48–55 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Selak, V. et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 105, 42 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Abushouk, A. I. et al. Fixed-dose combination (polypill) for cardiovascular disease prevention: a meta-analysis. Am. J. Prev. Med. 63, 440–449 (2022).

    Article 
    PubMed 

    Google Scholar 

  • United States Preventive Services Task Forceet al. Aspirin use to prevent cardiovascular disease. JAMA 327, 1577–1584 (2022).

    Article 

    Google Scholar 

  • Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924–926 (2008).

    Article 

    Google Scholar 

  • Agarwal, A. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases: a systematic review update. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=229735 (PROSPERO, 2021).

  • Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3. www.training.cochrane.org/handbook (Cochrane, 2011).

  • Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br. Med. J. 366, l4898 (2019).

    Article 

    Google Scholar 

  • Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 315, 629 (1997).

    Article 
    CAS 

    Google Scholar 

    • [ad_2]

    Source link